Canopy Growth Corp (CGC) Fair Value & Analysis
Healthcare · US · Market cap $434M · ISIN CA1380357048
Canopy Growth Corp
CGC · US
Risks
Fair value as of: Aug 27, 2026
From 1 valuation models · updated yesterday
Share price +12.4% over the past month.
Below-average quality, and trading another 103% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($0.7395). The favourable scenario is already priced in.
- Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($0.3655 to $0.7395) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
60‑month range $0.8280 – $260.90 · fair‑value band $0.3655 – $0.7395 · the $0.9995 price screens above the $0.4930 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 27, 2026.
Analysis
Canopy Growth Corp (CGC) currently trades at $0.9995, while our model-based Fair Value estimate is $0.4930, implying the stock looks roughly 50.7% overvalued today. The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Canopy Growth Corp generated revenue of $285M at a net margin of -92.4%. Revenue grew 9.6% year over year. It earns a return on equity of -44.4%. Net debt stands at $235M. Fundamentals as of Aug 27, 2026
Our scenario range runs from $0.3655 (bear case) to $0.7395 (bull case); at $0.9995, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 58% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -45% fair-value upside, at -51%, CGC screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when CGC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 26 · Market factors (momentum, volatility) 11
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works.
Full company description
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Canopy Growth Corp reported revenue of C$269M in FY2025 versus C$547M in FY2021, a compound −16.2%/yr. Reported net income was −C$598M in FY2025.
CGC screens 51% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 638 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | -24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | -38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | -69% |
| Haleon plc HLN | $9.80 | $7.62 | -22% |
| Teva Pharmaceutical Industries Limited TEVA | $37.92 | $15.33 | -60% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | -45% |
| Zoetis Inc ZTS | $77.52 | $104.88 | +35% |
| Hansoh Pharmaceutical Group 3692 | HK$33.50 | HK$16.14 | -52% |
Compare Canopy Growth Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Canopy Growth Corp (CGC) overvalued or undervalued?
What is the fair value of CGC?
What is the quality score of CGC?
What is the revenue of Canopy Growth Corp (CGC)?
What is the net profit margin of CGC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Canopy Growth Corp in the live analysis
One click puts Canopy Growth Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.